Sigachi Peer Comparison

NSE: SIGACHI | BSE: 543389

₹25.86

₹-0.50 (-1.90%)

As on 02-Nov-2026IST

Market cap

₹961 Cr

Revenue (TTM)

₹491 Cr

P/E Ratio

38.7

P/B Ratio

1.8

Div. Yield

0.4 %

Edit

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Market cap (₹ Cr)	961	32,243	31,939	17,972	16,732
Revenue (₹ Cr)	491	1,593	9,779	1,684	3,522
Net Profit (₹ Cr)	24.56	438.64	-270.51	-1.62	186.10
Net Margin (%)	4.97	27.16	-2.71	-0.10	5.15
RoE (%)	4.88	25.02	-2.55	0.22	4.93
Price to Earnings	38.68	73.42	--	--	89.91
Price-To-Book	1.78	17.36	3.92	3.04	3.44

Income Statement (₹ Cr)

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Operating Revenue	490.83	1,592.52	9,778.62	1,683.82	3,522.30
Total Income	493.88	1,615.23	9,993.26	1,695.30	3,613.20
Total Expenditure	433.09	969.32	8,578.44	1,287.94	2,771.50
EBITDA	57.75	623.20	1,200.18	395.88	750.80
Depreciation	17.59	41.96	887.82	288.26	449.10
EBIT	40.16	581.24	312.36	107.62	301.70
Interest	14.32	4.21	347.94	126.12	43.60
Other Income	3.04	22.71	214.64	11.47	90.90
Exceptional Items	-1.86	0.00	-216.88	-13.12	-96.80
Profit before Tax	27.02	599.74	-37.82	-20.14	252.20
Provision for Tax	2.46	161.10	232.69	-18.52	66.10
Profit after Tax	24.56	438.64	-270.51	-1.62	186.10

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Shareholder's Funds	539.63	1,857.45	8,142.24	5,920.89	4,858.80
Minority Interest	0.29	0.51	0.55	0.00	0.00
Non-Current Liabilities	38.53	47.15	5,213.99	1,001.58	616.80
Current Liabilities	288.79	253.37	5,158.51	1,663.61	1,182.90
Total Liabilities	841.17	1,983.96	17,723.32	8,222.05	7,054.70

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Non-Current Assets	335.41	1,132.12	10,687.30	6,364.60	3,950.40
Current Assets	412.36	1,012.00	7,253.65	1,697.49	1,948.10
Total Assets	841.17	1,983.96	17,723.32	8,222.05	7,054.70
Total Debt*	135.56	26.49	5,495.48	1,276.30	9.40
Net Current Assets	123.56	758.64	2,095.14	33.87	765.20
Contingent Liabilities	10.44	17.25	95.72	1,287.25	536.50

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Cash From Operating Activities	-42.80	292.17	1,652.60	8.52	915.20
Cash Flow from Investing Activities	-5.45	-265.94	-826.03	-494.98	-860.40
Cash from Financing Activities	2.24	4.10	-38.98	359.44	-215.00
Net Cash Inflow / Outflow	-46.01	30.33	787.59	-127.02	-160.20

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
ROCE (%)	-10.72	32.42	1.24	0.44	9.48
ROE (%)	4.88	25.02	-2.55	0.22	4.93
ROA (%)	2.85	22.40	-1.56	-0.02	2.82
EBIT Margin (%)	8.18	36.50	3.19	6.39	8.57
Net Margin (%)	4.97	27.16	-2.71	-0.10	5.15
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Revenue Growth (%)	-3.07	45.18	9.43	10.66	-5.99
EBIT Growth (%)	-46.54	115.51	-3.72	-55.98	-48.77
Net Profit Growth (%)	145.69	95.80	-199.34	-103.99	-60.25
EPS Growth (%)	-57.96	63.29	-410.28	-91.16	-49.04
Book Value Growth (%)	-13.17	26.03	0.33	-0.75	2.11

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Price / Earnings	38.94	74.62	-153.04	1,397.87	67.94
Price / Book Value	1.87	17.64	3.91	3.03	3.34
Dividend Yield (%)	0.38	0.06	0.00	0.00	0.31
EV/EBITDA	19.37	52.27	29.97	48.25	19.94
Market Cap (₹ Cr)	649.61	20,944.75	18,108.89	16,876.12	15,723.10

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Debt to Equity	0.00	0.02	0.55	0.10	0.00
Short term debt to equity ratio	0.26	0.00	0.09	0.10	0.00
Current Ratio	1.43	3.99	1.41	1.02	1.65
Quick Ratio	1.10	2.89	0.77	0.75	1.51
Interest Coverage	2.89	143.52	0.89	0.84	6.78

	Sigachi	Acutaas Chemicals	Piramal Pharma	Onesource Specialty Pharma	Syngene Intl
Debtors to sales (%)	47.70	22.50	23.05	61.34	10.94
Asset Turnover	0.57	0.81	0.56	0.20	0.53
Receivable days	155.78	88.98	78.20	140.79	50.33
Inventory Days	64.11	56.04	93.30	75.94	14.43
Payable days	69.59	99.95	226.14	225.76	17,487.50
Cash Conversion Cycle	150.30	45.07	-54.64	-9.03	-17,422.74

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.